hold on there's just too much going on in Congress lmao...
Exempts certain traditional and premium cigars from most FDA regulation.
Introduced by Senator Moody (R-FL) and Senator Scott (R-FL).
Introduced in the Senate, referred to committee.
This bill, introduced by Senators Moody and Scott, aims to remove most traditional large and premium cigars from the Food and Drug Administration's (FDA) regulatory authority. It was introduced in the Senate and has been sent to the Committee on Health, Education, Labor, and Pensions for review. This means it's in the early stages and has not yet been voted on by the full Senate.
Introduced Feb 25, 2026
This bill is currently in the 'Introduced' stage in the Senate. It was referred to the Committee on Health, Education, Labor, and Pensions. For it to become law, it would need to pass through this committee, be voted on and passed by the full Senate, then be voted on and passed by the House of Representatives, and finally signed into law by the President. There are no known dates for further action at this time.
If this bill passes, a specific category of 'traditional large and premium cigars' would be largely excluded from the FDA's regulatory powers, except for rules regarding tobacco leaf. This means the FDA would not be able to create or enforce regulations concerning the manufacturing, marketing, or sale of these particular cigar products. For businesses, this could mean reduced compliance burdens, while consumers might encounter these cigars without the same federal scrutiny applied to other tobacco products, potentially affecting information available about them.
Supporters Say
Supporters believe this bill will protect jobs and small businesses involved with traditional and premium cigars by reducing federal regulation.
Critics Say
The bill text does not explicitly state arguments from critics.
The bill's stated purpose is 'to protect jobs and small businesses involved in the sale, manufacturing, and distribution of traditional and premium cigars' by clarifying that the FDA has limited authority over these products. Arguments from critics are not detailed within the bill's text; however, such legislation generally sparks debate regarding public health implications of reduced regulatory oversight on tobacco products.